Fexuprazan

Fexuprazan
Clinical data
Trade names	Fexuclue
Other names	Abeprazan; DWP14012; DWP-14012
ATC code	None;
Legal status
Legal status	Rx in South Korea, Mexico;
Identifiers
	IUPAC name 1-[5-(2,4-Difluorophenyl)-1-(3-fluorophenyl)sulfonyl-4-methoxypyrrol-3-yl]-N-methylmethanamine;
CAS Number	1902954-60-2;
PubChem CID	122662112;
DrugBank	DB16078;
ChemSpider	68006985;
UNII	BE52S2C1QT;
ChEMBL	ChEMBL4594445;
Chemical and physical data
Formula	C19H17F3N2O3S
Molar mass	410.41 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNCC1=CN(C(=C1OC)C2=C(C=C(C=C2)F)F)S(=O)(=O)C3=CC=CC(=C3)F;
	InChI InChI=1S/C19H17F3N2O3S/c1-23-10-12-11-24(28(25,26)15-5-3-4-13(20)8-15)18(19(12)27-2)16-7-6-14(21)9-17(16)22/h3-9,11,23H,10H2,1-2H3; Key:OUNXGNDVWVPCOL-UHFFFAOYSA-N;

Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD).^[1] It is a potassium-competitive acid blocker.^[2]

Fexuprazan is approved for use in South Korea and Mexico.^[3]^[4]

References[edit]

^ Ramani A, Merchant A, Cash BD (August 2023). "Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease". European Journal of Clinical Pharmacology. 79 (8): 1023–1029. doi:10.1007/s00228-023-03521-4. PMID 37344679. S2CID 259222741.
^ Kim GH, Choi MG, Kim JI, Lee ST, Chun HJ, Lee KL, et al. (November 2023). "Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis". Gut and Liver. 17 (6): 884–893. doi:10.5009/gnl220457. PMC 10651377. PMID 36789577.
^ "펙수클루정40밀리그램(펙수프라잔염산염)" [Fexuclue tablets 40 mg (fexuprazan hydrochloride)]. nedrug.mfds.go.kr (in Korean).
^ "Daewoong Pharma's GER drug gets product OK from Mexico". Korea Economic Daily. October 19, 2023.